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Abstract 
Background: The mitochondrial enzyme amyloid beta-binding alcohol dehydrogenase (ABAD) 
also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) has been connected with the 
pathogenesis of Alzheimer’s disease (AD). ABAD/ 17β-HSD10 is a binding site for the amyloid-beta peptide 
(Aβ) inside the mitochondrial matrix where it exacerbates Aβ toxicity. Interaction between these two 
proteins triggers a series of events leading to mitochondrial dysfunction as seen in AD. Methods: As ABAD’s 
enzymatic activity is required for mediating Aβ toxicity, its inhibition presents a promising strategy for AD 
treatment. In this study, a series of new benzothiazolylurea analogues have been prepared and evaluated 
in vitro for their potency to inhibit ABAD/ 17β-HSD10 enzymatic activity. The most potent compounds have 
also been tested for their cytotoxic properties and their ability to permeate through blood-brain barrier 
has been predicted. To explain the structure-activity relationship QSAR and pharmacophore studies have 
been performed.  Results and Conclusions: Compound 12 was identified being the most promising hit 
compound with good inhibitory activity (IC50 = 3.06 ± 0.40µM) and acceptable cytotoxicity profile 
comparable to the parent compound of frentizole. 
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The satisfactory physical-chemical properties suggesting its capability to permeate through BBB 
make compound 12 a novel lead structure for further development and biological assessment. 
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Introduction 
Alzheimer’s disease (AD) is the most common cause of senile dementia. About 20 million people 
worldwide suffer from this devastating illness [1]. AD is characterized by progressive decline of cognitive 
functions and memory. Despite intensive research, the pathogenic mechanisms of AD are still not fully 
understood and consequently no effective treatment has been yet developed. 
The main pathological hallmarks of AD represents extracellular amyloid-beta peptide (Aβ) 
deposits also termed senile plaques, intracellular deposits of phosphorylated τ-protein, termed 
neurofibrillary tangles, and loss of neurons [2,3]. Although the aetiology of AD is still not known, buildup 
of Aβ is considered to play an important part in disease progression. The original amyloid cascade 
hypothesis suggested that extracellular plaques are the main toxic form of Aβ. However, recent data 
indicates that soluble intracellular oligomers are responsible for most of Aβ toxicity [4–8]. 
Inside the cell, Aβ interacts with a number of proteins including amyloid-binding alcohol 
dehydrogenase (ABAD), also referred as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) [9], an 
enzyme located within mitochondrial matrix capable to catalyse oxidation of alcohols and reduction of 
aldehydes and ketones. 
As cells expressing catalytically inactive mutants of ABAD/ 17β-HSD10 show decreased sensitivity 
to Aβ, it has been suggested that the ABAD/ 17β-HSD10 enzymatic activity is required for mediating Aβ 
toxicity [10]. Therefore, inhibition of ABAD/ 17β-HSD10 is a possible strategy for AD treatment, which has 
already been indicated with the use of a small molecule ABAD/ 17β-HSD10 inhibitor AG18051. AG18051 
is an irreversible ABAD/ 17β-HSD10 inhibitor reported to create a covalent bond with the cofactor NAD+ 
within the enzyme’s active site, and was shown subsequently to ameliorate Aβ toxicity in cell based studies 
[11,12]. 
Previously, frentizole and its analogues were found to be inhibitors of the ABAD-Aβ interaction, 
which presents another approach of targeting ABAD/ 17β-HSD10 for AD treatment [13,14]. Assuming that 
this effect was due to binding of these compounds to ABAD/ 17β-HSD10, some frentizole analogues were 
also tested as ABAD/ 17β-HSD10 inhibitors, which led to the discovery of a novel class of ABAD/ 17β-
HSD10 inhibitors [15]. Similarly to AG18051, this new class of ABAD/ 17β-HSD10 inhibitors have 
cytoprotective effects in cells treated with Aβ [12,15]. 
Additionally to AD treatment ABAD/ 17β-HSD10 inhibition could be also employed in treatment 
of certain types of prostatic cancer, where overexpression of ABAD/ 17β-HSD10 takes place allowing the 
cancer cells to generate 5α-dihydrotestosterone in the absence of testosterone [16,17]. 
However, currently known ABAD/ 17β-HSD10 inhibitors (Fig. 1) suffer from some considerable 
drawbacks making them poor lead drug-like candidates. Compound AG18051 creates a covalent bond 
with NAD+ cofactor within the enzyme’s active site and with such mechanism of action it is likely to affect 
also other NAD+ dependant enzymes [11]. Compound RM-532-46 could suffer from specificity 
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issues as well, because it comprises a steroidal structural scaffold, which could be recognized by other 
steroid-binding sites [18]. Recently identified phosphonate-benzothiazole inhibitors showed rather poor 
activity with best compound having IC50 value of 52.7 μM [15]. Hence there is a need for developing novel 
ABAD/ 17β-HSD10 inhibitors with improved properties. 
 
Figure 1: Currently known ABAD/ 17β-HSD10 inhibitors and their IC50 values. 
In this study we have designed, synthesized and evaluated in vitro a series of novel 6-
benzothiazolyl ureas, thioureas and guanidines. The most promising compounds have been further 
assessed for their cytotoxic properties and ability to cross the blood-brain barrier (BBB). 
2. MATERIALS AND METHODS 
2.1 General chemistry 
Solvents and reagents were purchased from Fluka and Sigma-Aldrich (Czech Republic) and 
used without further purification. Reactions were monitored by TLC performed on aluminium sheets 
precoated with silica gel 60 F254 (Merck, Czech Republic) using mobile phase CHCl3/MeOH 50:1 – 5:1 
and detected under 254 nm UV light. Column chromatography was performed on silica gel 60 (230 
mesh). Melting points were measured on Stuart SMP30 melting point apparatus (Bibby Scientific 
Limited, Staffordshire, UK) and are uncorrected. 
NMR spectra were recorded at Varian Gemini 300 (1H 300 MHz, 13C 75 MHz, Palo Alto CA, USA) 
or Varian S500 (1H 500 MHz, 13C 126 MHz, Palo Alto CA, USA). In all cases, the chemical shift values for 1H 
spectra are reported in ppm (δ) relative to residual CHD2SO2CD3(δ 2.50), shift values for 13C spectra are 
reported in ppm (δ) relative to solvent peak dimethylsulfoxide-d6  (δ 39.52) [19]. 
Mass spectra (MS, respectively, MSn) were recorded on a LTQ XL linear ion trap mass 
spectrometer and evaluated using Xcalibur v 2.5.0 software (both Thermo Fisher Scientific, San Jose, CA, 
USA). The sample was dissolved in methanol (HPLC grade; Sigma-Aldrich, Prague, Czech Republic) and 
injected continuously (10 µL/min) by using a Hamilton syringe into the electrospray ion source. The 
parameters of electrospray were set up as follows: sheath gas flow rate 20 arbitrary units, aux gas 
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flow rate 10 arbitrary units, sweep gas flow rate 0 arbitrary units, spray voltage 4.5 kV, capillary 
temperature 275 °C, capillary voltage 13 V, tube lens 100 V. 
For HRMS determination, a Dionex UltiMate 3000 analytical LC-MS system coupled with a Q 
Exactive Plus hybrid quadrupole-orbitrap spectrometer (both produced by ThermoFisher Scientific, 
Bremen, Germany) was used. The LC-MS system consisted of a binary pump HPG-3400RS connected to 
a vacuum degasser, a heated column compartment TCC-3000, an autosampler WTS-3000 equipped with 
a 25 μL loop and a VWD-3000 ultraviolet detector. A Waters Atlantis dC18 100Å (2.1 x 100mm/3µm) 
column was used as the stationary phase. The analytical column was protected against mechanical 
particles by an in-line filter (Vici Jour) with a frit of 0.5µm pores. Water (MFA) and acetonitrile (MFB) 
used in the analyses were acidified with 0.1% (v/v) of formic acid. Ions for mass spectrometry (MS) were 
generated by heated electro-spray ionization source (HESI) working in positive mode, with the following 
settings: sheath gas flow rate 40, aux gas flow rate 10, sweep gas flow rate 2, spray voltage 3.2 kV, 
capillary temperature 350°C, aux gas temperature 300°C, S-lens RF level 50, microscans 1, maximal 
injection time 35ms, resolution 140 000. The full-scan MS analyses monitored ions within m/z range 100 
– 1500. The studied compounds were dissolved in methanol and 1µL of the solution was injected into 
the LC-MS system. For elution, following ramp-gradient program was used: 0 – 1 min: 10% MFB, 1 – 4 
min: 10% – 100% MFB, 4 – 5 min: 100% MFB, 5 – 7.5 min: 10% MFB. The flow-rate in the gradient elution 
was set to 0.4 mL/min. To increase the accuracy of HRMS, internal lock-mass calibration was employed 
using polysiloxane traces of m/z = 445.12003 ([M+H]+, [C2H6SiO]6) present in the mobile phases. The 
chromatograms and mass spectra were processed in Chromeleon 6.80 and Xcalibur 3.0.63 software, 
respectively. 
Elemental analysis (EA) was measured at Perkin-Elmer CHN Analyser 2400 Series II apparatus. 
2.2 Physical-chemical properties calculation and measurement 
Physical-chemical properties of prepared compounds in the unionized form were calculated in 
ACDLabs PhysChem Suite 2014 [20]. 
The method of measurement and calculation of ElogP was adapted from Technical guide OECD 
No. 117 [21]. Based on this method, the ElogD was determined accordingly [22]. All chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Seven standard stock solutions were prepared by 
dissolving nitrobenzene (ReagentPlus, 99%), chlorobenzene (puriss. p.a., ACS reagent, ≥99.5%), thymol 
(≥99.0%), biphenyl (ReagentPlus, 99.5%), butylbenzene (≥99%), fluoranthene (98%) and 4,4′-DDT (98%) 
in HPLC grade methanol and stored in the refrigerator at temperature of 4 °C. Mixed standard solution 
was prepared prior analysis by adding each of the stock standard solutions (100 µL) to 1.5 mL glass vial 
and addition of HPLC grade methanol (300 µL). Standard solution for dead time measurement was 
prepared by dissolving of citric acid (1 mg) in 70% solution of HPLC grade methanol and 30% 
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distilled water (1 mL). The Tris-HCl buffer for mobile phase was prepared from 0.05 M 
tris(hydroxymethyl)aminomethane solution by adjusting by 1 M HCl to pH 7.4. The pH measurement 
was carried by multimeter inoLab Multi 9430 IDS (WTW, Weilheim, DEU) with attached electrode 
SenTix Mic (WTW, Weilheim, DEU), DuraCal pH buffers (Hamilton, Bonduz, CHE) were used for 
calibration of pH electrode. All used water was prepared by Ultrapore Simplicity Water Purification 
System type 1 (Merck Millipore, Billerica, MA, USA). 
The synthesized sample (1 mg) was dissolved in solution of 70% HPLC grade methanol and 30% 
distilled water (1 mL). Sample solutions were centrifuged using an Eppendorf Centrifuge 5418 
(Eppendorf, Hamburg, Germany) for 10 minutes in frequency of 14000 rounds per minute and 0.9 mL 
of centrifuged supernatants was transferred to 1.5 mL glass vials. The analysis was performed by HPLC 
system Infinity 1260 (Agilent Technologies, Santa Clara, CA, USA) with Infinity 1290 auto sampler 
(G4226A), Infinity 1260 Quaternary LC pump (G1311B), Infinity 1260 Thermostatted Column 
Compartment (G1316A), and Infinity 1260 Diode-Array Detector (G4212B). Used LC column was 
Kinetex® 5 µm C18 100 Å, 100 x 4.6 mm (Phenomenex, Torrance, CA, USA) with attached 
SecurityGuardTM system for C18 HPLC column (Phenomenex, Torrance, CA, USA). Duration of the 
analysis was set to 60 min in flow rate of mobile phases 1 mL/min and at a temperature of 20 °C within 
the column. Dosage of sample and standard solution from autosampler was set to 10 μL. There was 
isocratic flow of mobile phases with 70% HPLC grade methanol and 30% distilled water for ElogP 
measurement and 70% HPLC grade methanol and 30% 0.05 M Tris-HCl buffer (pH 7.4) for ElogD 
measurement respectively. Both, analyses of standard solution and sample solutions were performed 
in triplicate. 
The capacity factors (Eq. 1) were calculated from retention times of samples or standards: 
k = tr−t0 (Eq. 1) 
t0 
k = capacity factor; t0 = dead time (retention time of citric acid); tr = retention time of sample 
The ElogP values were calculated (Eq. 2). Linear regression coefficients were obtained from 
linear regression of ElogP of standard solutions against the log of their capacity factors. The ElogD 
values were calculated from measurement with 0.05 M Tris-HCl buffer (pH 7.4) as mobile phase B, 
using same standard solutions and equations. 
ElogP = a + b × logk (Eq. 2) 
P = octanol/water partition coefficient; a, b = linear regression coefficients; k = capacity factor 
2.3 ABAD/ 17β-HSD10 Purification and Initial Compound Screens 
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Recombinant ABAD/ 17β-HSD10 was purified from E.coli as described in Aitken et al. 2016 
[23]. Hroch et al. 2016 [24] was used as a reference to assess the capability of the synthesised 
benzothiazole urea analogues to modulate ABAD/ 17β-HSD10 activity, two initial compound screens 
were performed. Reaction conditions consisted of ABAD enzyme (0.5 μg/mL, 18.52 nM), NADH (250 
μM), acetoacetyl-CoA (120 μM) and a single compound of interest (25 μM or 100 μM) (1% DMSO 
(v/v)). Solutions were prepared in assay buffer (10 mM HEPES buffer, pH 7.4 at 37 °C). Control 
solutions containing an equivalent concentration of DMSO (1% (v/v)) were also prepared and run 
concurrently. Reaction progression was measured via a decrease in NADH absorbance at 340 nm 
using a SpectraMAX M2e spectrophotometer. A reaction time of 200 s was employed yielding steady 
state conditions (R2 > 0.9). 
A test for compound active site cysteine residue binding was performed by comparing the 
inhibition observed with compounds 5 and 12 using the conditions described for the initial 
compound screen, in the presence and absence of DTT (5 mM). 
Dose Response Relative IC50 values were measured using the reaction conditions outlined 
for the initial compound screen, the inhibitory nature of promising compounds was assessed over a 
range of concentrations (250 μM to 10 nM). Statistical analysis was performed with using GraphPad 
Prism. 
To validate in-house ABAD assay, an IC50 curve was generated for compound AG18051 (the 
Kissinger inhibitor), a known potent inhibitor of the ABAD enzyme. An IC50 value of 69 nM was 
generated for compound AG18051 (Fig. 2), comparable to the 92 nM reported previously by 
Kissinger et al., using a cell based system [25], thus providing evidence that our screening assay is 
robust in  nature.  
 
Figure 2: Dose response for compound AG18051. Values shown are an average ± SEM taken from two 
experiments each with three technical repeats. 
2.4 QSAR analyses and Pharmacophore modelling 
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The relationship between the structures of the studied compound 1-15 and their inhibition 
potency towards ABAD/178-HSD10 was analysed by a systematic QSAR analysis. All compounds 
were prepared for QSAR analyses in HyperChem 8.0 [26]  by running a 10 ps long molecular dynamic 
simulation at constant temperature 310.15K (step 1 fs, bath relaxation time 0.1 ps) using a semi-
empirical method PM3. After the molecular dynamic simulation phase, the structures were 
geometrically optimized by Polak-Ribiére conjugate algorithm employing the same PM3 method 
with the convergence criterion set to 0.03 kcal/(Å.mol). The optimized structures along with the 
calculated Mulliken charges were imported into Dragon 6 program to generate 4885 various 
molecular descriptors (e.g. constitutional indices, topological indices, information indices, 2D matrix 
based  descriptors, geometrical descriptors, 3D-MoRSE descriptors, WHIM descriptors, GETAWAY 
descriptors, drug-like properties, etc.) [27]. The matrix of molecular descriptors and the relative 
ABAD/17β-HSD10 inhibitions caused by 25 mM were processed in a self-developed C++ based 
program Statoo using multiple linear regression (MLR) and an exhaustive combinatorial variable 
selection algorithm  evaluating every k-set of molecular descriptors [28]. With the respect to 
recommended ratio of 1 predictor to 5 or more compounds, we investigated all possible MLR QSAR 
models containing at most 3 molecular descriptors [29]. The final MLR QSAR top-scoring model was 
evaluated by leave-one-out, leave-30%-out cross-validation, and also by randomization and 
scrambling the vector of biological activities [30]. The domain of applicability of the best MLR QSAR 
model was checked by Williams plot in Matlab 2015.  
In order to reveal the most significant structural features of the studied compound for the 
observed biological activity (i.e. at concentration 25 mM), a pharmacophore analysis was performed. 
Initially, the models of 1-15 were prepared by quenched molecular dynamics (QMD) in Open3DAlign 
program [31], which uses Tinker to perform molecular mechanics calculations with MMFF94 force 
field. The QMD protocol was set to carry out a 10 ps simulation at 1000K in vacuum (step size 0.1 fs) 
and to minimize the geometry till the gradient achieved 0.001 kcal/(Å.mol) or the number of 
iterations exceeded 1000. For each compound in the set, a conformer library was prepared to be 
screened in 3D alignment process. A hybrid approach mixing Pharao pharmacophore-based [32] and 
LAMBDA-like [33] algorithms in Open3DAlign program was utilized to find the best superimposition 
of all the studied structures on compound 12. Within the alignment process, all combinations 
between 12 conformers and the other compounds’ conformers were aligned to find a 
superimposition exhibiting maximal O3A score [34]. The best molecular superimposition in the sense 
of the highest O3A score was investigated by a pharmacophore analysis in LigandScout 3.1 program 
to derive the substructure influencing most significantly the biological activity. The pharmacophore 
hypothesis was derived using the most active compounds as a training set.  
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2.5 Cell viability assessment 
The effect of compounds on the cell viability was examined using methodology combining 
LDH and MTT assay into one experimental setup. Such an assay has been chosen due to the fact 
that widely used MTT test is partially dependent on the mitochondrial oxidoreductases [35], whose 
activity might be influenced by the tested compounds targeted to mitochondria. The protocol for 
this assay has been described previously [36]. Briefly CHO cell line (Chinese hamster ovary, CHO-
K1WT2, CRL-1984 ECACC, Salisbury, UK) were cultured according to ECACC recommended 
conditions and seeded in a density of 8 000 cells per well as was described earlier [37]. Tested 
compounds were dissolved in DMSO and subsequently in the growth medium (F-12) 
supplemented with 1% PEN/STREP without FBS so that the final concentration of DMSO did not 
exceed 0.5% (v/v). Cells were exposed to a tested compound in the medium (100 µL) for 24 hours. 
Then 10 μL of MTT (2.5 mg/mL in buffer) was added and 50 μL of the culture supernatant was 
transferred to a new plate yet containing 50 μL of LDH substrate mixture consisting of lactate (2.5 
mg/mL), NAD (2.5 mg/mL), phenazine methansulphate (100 µM) and Triton X-100 (0.1%) in Tris–
HCl buffer (pH 8.2). LDH reaction mixture was incubated at 37 °C for 15-30 min until the difference 
between negative (no treatment) and positive control (0.1% Triton X-100) was obvious. Cellular 
fraction containing MTT was allowed to produce formazan for another approximately 3 h at 37°C. 
Thereafter, medium with MTT was removed and crystals of formazan were dissolved in DMSO (100 
µL). Absorbance was measured at 570 nm with 650 nm reference wavelength on Synergy HT 
reader (BioTek, USA) for both LDH and MTT fraction. IC50 was then calculated from the control - 
subtracted triplicates using non-linear regression (four parameters) of GraphPad Prism 5 software. 
Final IC50 and SEM value was obtained as a mean of at least 3 independent measurements (in 
triplicate). 
3. EXPERIMENTAL 
3.1 Chemical preparation 
2-aminobenzo[d]thiazole-6-carboxylate 
Ethyl 4-aminobenzoate (1 eq.) and KSCN (4 eq.) were dissolved in acetic acid (4 mL/mmol) 
and stirred at rt for 20 mins. Then the reaction mixture was cooled to 10 °C and bromine (2 eq.) 
dissolved in small amount of acetic acid was added dropwise. Afterwards the reaction mixture was 
left to warm up to rt and stirred overnight. After the reaction was completed (monitored by TLC), 
reaction mixture was added dropwise into the sat. aq. NH3 solution (15 mL/mmol) while cooling in 
an ice bath. The product was extracted to EtOAc and the organic layer was washed with Na2S2O3, 
sat. aq. NaHCO3 and brine, dried using anhydrous Na2SO4 and concentrated under reduced 
pressure. The crude product was either recrystallized from diethylether to obtain ethyl 2-
aminobenzo[d]thiazole-6-carboxylate in 69% yield. 
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1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.27 (d, J = 1.8 Hz, 1H), 7.88 (s, 2H), 7.81 (dd, J = 8.4, 1.8 Hz, 
1H), 7.36 (d, J = 8.4 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
General procedure for synthesis of N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamides 
Corresponding 2-aminobenzo[d]thiazole (1 eq.) was dissolved in a mixture of 
dimethylformamide (DMF) and dichloromethane (DCM) (1:6; 12 mL/mmol), 1,1’-carbonyldiimidazole 
(CDI; 1.2 eq.) was added and the reaction mixture was stirred vigorously at reflux overnight. The 
resulting precipitate was collected by filtration, washed with DCM and dried to obtain corresponding N-
(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamide as a white solid in excellent yield (90 - 97 %). 
General procedure for synthesis of N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carbothioamides 
Corresponding 2-aminobenzo[d]thiazole (1 eq.) was dissolved in acetonitrile (MeCN; 5 
mL/mmol), 1,1’-thiocarbonyldiimidazole (SCDI; 1.2 eq.) was added and the reaction mixture was 
stirred at reflux overnight. The resulting precipitate was collected by filtration, washed with DCM 
and dried to obtain corresponding N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carbothioamide as a 
pale yellow solid in medium to excellent yield (65 - 95 %). 
General procedure for synthesis of 1-(benzo[d]thiazol-2-yl)-3-phenylureas resp. 1-(benzo[d]thiazol-2-
yl)-3-phenylthioureas 
Corresponding N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamide resp. N-  
(benzo[d]thiazol-2-yl)-1H-imidazole-1-carbothioamide (1 eq.) was dissolved in DMF (8 mL/mmol), the 
corresponding aniline derivative (1.1 eq.) was added and the reaction mixture was stirred at 60 °C. 
After the reaction was completed (monitored by TLC), the reaction mixture was portioned with 1 M 
HCl aqueous solution (for carboxyl group containing aniline derivatives). The resulting precipitate was 
collected by filtration, washed with water and dried to obtain corresponding 1-(benzo[d]thiazol-2-yl)-
3-phenylurea or 1-(benzo[d]thiazol-2-yl)-3-phenylthiourea in medium to excellent yield (60 - 96 %). 
General procedure for synthesis of 1-(benzo[d]thiazol-2-yl)-3-phenylguanidines 
The corresponding thiourea derivative (1 eq.) was dissolved in 7N methanolic ammonia solution 
(12 mL/mmol), mercury oxide (3 eq.) was added and the reaction mixture was stirred at room 
temperature overnight. After the reaction was completed (monitored by TLC), the reaction mixture was 
filtered over Celite and washed with either THF or MeOH (40 mL/mmol). Evaporation of the filtrate gave 
corresponding guanidine in poor to good yield (10–79 %). In cases, where further purification was 
required, the procedure is described together with the respective compound’s characterization. 
10 
Preparation of hydrochloride salt from guanidine base 12 
The guanidine 12 was dissolved in THF, purged with diethylether saturated with gaseous 
hydrochloric acid and stirred for 1 h at 0 °C. The resulting precipitate was collected by filtration 
and washed with diethyl ether to obtain guanidine hydrochloride as white solid (90%). 
3.2 Prepared compounds and their characterization 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylurea (1, frentizole) 
M.p. 328–330 °C. Yield 91%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.68 (br s, 1H), 9.13 (br s, 1H), 
7.56 (d, J = 8.8 Hz, 1H), 7.54 – 7.47 (m, 3H), 7.33 (t, J = 7.9 Hz, 2H), 7.05 (t, J = 7.3 Hz, 1H), 6.98 (dd, 
J = 8.8, 2.6 Hz, 1H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 157.68, 155.87, 152.01, 
142.82, 138.66, 132.61, 129.10, 123.08, 120.29, 118.95, 114.55, 105.12, 55.78. ESI-HRMS: 
m/z300.07986 [M+H]+ (calc. for C15H13N3O2S: 300.08012[M+H]+). 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylthiourea (2) 
M.p. 198–200 °C. Yield 88%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.51 (br s, 1H), 10.80 (br s, 1H), 
7.70 (d, J = 7.9 Hz, 2H), 7.49 (m, 2H), 7.35 (t, J = 7.4 Hz, 2H), 7.14 (s, 1H), 7.02 (dd, J = 8.8, 2.3 Hz, 1H), 
3.79 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 181.42, 156.09, 139.38, 128.44, 124.17, 122.87, 
114.74, 105.93, 55.68; ESI-HRMS: m/z316.05685 [M+H]+ (calc. for C15H13N3OS2: 316.05728[M+H]+). 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylguanidine (3) 
The crude product was recrystallized from petroleum ether. 
M.p. 129.5–131 °C. Yield79 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.04 (br s, 1H), 7.96 (br s, 2H), 
7.48 (dd, J = 8.5, 0.9 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.08 – 
7.01 (m, 1H), 6.90 (dd, J = 8.8, 2.7 Hz, 1H), 3.77 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.47, 
155.27, 153.69, 145.64, 138.93, 131.80, 128.82, 122.83, 120.68, 119.53, 113.54, 104.94, 55.52. ESI-
HRMS: m/z 299.09564 [M+H]+ (calc. for C15H14N4OS: 299.09611[M+H]+). 
1-(6-fluorobenzo[d]thiazol-2-yl)-3-phenylurea (4) 
M.p. 362.5–364.4 °C. Yield 76%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.77 (br s, 1H), 9.06 (br s, 1H), 
7.79 (dd, J = 8.7, 2.6 Hz, 1H), 7.71 – 7.61 (m, 1H), 7.51 (d, J = 7.8 Hz, 2H), 7.34 (t, J = 7.9 Hz, 2H), 7.21 (td, 
J = 9.2, 2.7 Hz, 1H), 7.07 (t, J = 7.4 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.20, 158.14 (d, J = 
239.3 Hz), 151.64, 144.93, 138.10, 132.39, 128.63 (d, J = 15.5 Hz), 122.84 (d, J = 8.3 Hz), 120.28, 118.79 
(d, J = 16.6 Hz), 113.48 (dd, J = 24.3, 14.2 Hz), 107.70 (dd, J = 26.9, 13.5 Hz). ESI-HRMS: m/z288.05988 
[M+H]+ (calc. for C14H10FN3OS: 288.06014[M+H]+). 
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1-(6-fluorobenzo[d]thiazol-2-yl)-3-phenylthiourea (5) 
M.p. 302 °C decomp. Yield 84%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.52 (br s, 1H), 10.81 (br s, 
1H), 7.81 (dd, J = 9.0, 2.1 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.55 (s, 1H), 7.36 (t, J = 7.9 Hz, 2H), 7.27 (td, J 
= 9.2, 2.5 Hz, 1H), 7.21 – 7.06 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ (ppm) 180.89, 158.50 (d, J = 
239.2 Hz), 157.48, 139.25, 128.48, 124.52, 123.21, 114.37 (d, J = 24.6 Hz), 108.97 (d, J = 27.2 Hz); ESI-
HRMS: m/z304.03711 [M+H]+ (calc. for C14H10FN3S2: 304.03729[M+H]+). 
1-(6-fluorobenzo[d]thiazol-2-yl)-3-phenylguanidine (6) 
The crude product was recrystallized from petroleum ether/heptan. 
M.p. 166–168 °C. Yield 32%. 1H NMR (500 MHz, CD3OD): δ (ppm) 7.51 (dd, J = 8.8, 4.8 Hz, 1H), 7.44 – 7.33 
(m, 5H), 7.15 (tt, J = 7.4, 1.3 Hz, 1H), 7.03 (td, J = 9.1, 2.7 Hz, 1H). 13C NMR (126 MHz, CD3OD): δ (ppm) 
174.60, 160.27 (d, J = 239.6 Hz), 156.54, 149.69, 139.25, 133.70 (d, J = 10.7 Hz), 130.28, 125.78, 123.96, 
121.04 (d, J = 8.9 Hz), 114.00 (d, J = 24.3 Hz), 108.14 (d, J = 27.0 Hz). ESI-HRMS: m/z287.07584 [M+H]+ 
(calc. for C14H11FN4S: 287.07612[M+H]+). 
ethyl 2-(3-phenylureido)benzo[d]thiazole-6-carboxylate (7) 
M.p. 314–316 °C. Yield 59%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.12 (br s, 1H), 9.23 (br s, 1H), 8.56 
(d, J = 0.8 Hz, 1H), 7.97 (dd, J = 8.5, 1.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 7.7 Hz, 2H), 7.34 (t, J = 
7.9 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 165.49, 162.76, 151.89, 138.25, 131.45, 128.93, 127.06, 124.17, 123.41, 123.13, 
119.08, 118.88, 60.64, 14.23. ESI-HRMS: m/z 342.09009 [M+H]+ (calc. for C17H15N3O3S: 342.09069[M+H]+) 
ethyl 2-(3-phenylthioureido)benzo[d]thiazole-6-carboxylate (8) 
M.p. 207.5–208.8 °C. Yield 88%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.61 (s, 1H), 8.48 (s, 1H), 7.99 
(dd, J = 8.4, 1.6 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.60 (s, 1H), 7.37 (t, J = 6.9 Hz, 2H), 7.16 (s, 1H), 4.33 (q, 
J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 181.89, 165.35, 156.99, 
139.18, 128.55, 128.48, 127.74, 124.73, 124.01, 123.41, 112.48, 60.79, 14.27. ESI-HRMS: 
m/z358.06760 [M+H]+ (calc. for C17H15N3O2S2: 358.06784[M+H]+). 
ethyl 2-(3-phenylguanidino)benzo[d]thiazole-6-carboxylate (9) 
The crude product was recrystallized from petroleum ether/heptan. 
M.p. 134–136 °C. Yield 28%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.31 (br s, 1H), 8.36 (s, 1H), 8.14 (br s, 
1H), 7.89 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 7.1 Hz, 2H), 7.36 (t, J = 7.7 Hz, 2H), 7.10 (t, J 
= 7.1 Hz, 1H), 4.31 (dd, J = 14.0, 6.9 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-
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d6): 6 (ppm) 176.24, 165.56, 155.35, 154.57, 138.31, 130.74, 128.93, 126.78, 123.54, 122.58, 121.43, 
118.38, 60.49, 14.23. ESI-HRMS: m/z341.10617 [M+H]+ (calc. for C17H16N4O2S: 341.10667[M+H]+). 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)urea (10) 
M.p. 316–318 °C. Yield 87%. 1H NMR (500 MHz, DMSO-d6): 6 (ppm) 10.59 (br s, 1H), 8.94 (br s, 1H), 7.55 
(d, J = 8.7 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.41 (d, J = 8.7 Hz, 2H), 6.98 (dd, J = 8.7, 2.2 Hz, 1H), 6.91 (d, J 
= 8.8 Hz, 2H), 3.79 (s, 3H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): 6 (ppm) 157.57, 155.64, 155.20, 
151.87, 142.77, 132.48, 131.38, 120.70, 120.16, 114.30, 114.09, 104.92, 55.59, 55.20. ESI-HRMS: 
m/z330.09015 [M+H]+ (calc. for C16H15N3O3S: 330.09069[M+H]+). 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)thiourea (11) 
M.p. 202.2–202.7 °C. Yield 90%. 1H NMR (500 MHz, DMSO-d6): 6 12.33 (br s, 1H), 11.04 (br s, 1H), 
7.60 – 7.40 (m, 4H), 7.01 (dd, J = 8.8, 2.6 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.76 (s, 3H). 
13C NMR (126 MHz, DMSO-d6): 6 (ppm) 179.76, 160.68, 156.49, 156.06, 138.31, 132.03, 129.52, 
125.22, 118.05, 114.61, 113.63, 105.76, 55.66, 55.24. ESI-HRMS: m/z346.06763 [M+H]+ (calc. for 
C16H15N3O2S2: 346.06784[M+H]+). 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)guanidine (12) 
M.p. 160.5–161.7 °C. Yield 72%. 1H NMR (500 MHz, DMSO-d6): 6 (ppm) 8.96 (br s, 1H), 7.82 (s, 1H), 7.43 
(d, J = 8.8 Hz, 1H), 7.37 – 7.29 (m, 3H), 6.96 – 6.91 (m, 2H), 6.89 (dd, J = 8.8, 2.6 Hz, 1H), 3.76 (s, 3H), 3.74 
(s, 3H). 13C NMR (126 MHz, DMSO-d6): 6 (ppm) 171.74, 155.71, 155.14, 154.33, 145.77, 131.66, 131.35, 
123.57, 119.28, 114.15, 113.37, 104.97, 55.51, 55.22. ESI-HRMS: m/z329.10632 [M+H]+ (calc. for 
C16H16N4O2S: 329.10667[M+H]+). 
4-(3-(6-methoxybenzo[d]thiazol-2-yl)ureido)benzoic acid (13) 
M.p. 295 °C decomp. Yield 96%. 1H NMR (500 MHz, DMSO-d6): 6 (ppm) 10.52 (br s, 1H), 8.75 (br s, 
1H), 7.94 – 7.89 (m, 2H), 7.67 – 7.61 (m, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 2.6 Hz, 1H), 7.00 
(dd, J = 8.8, 2.6 Hz, 1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): 6 (ppm) 166.96, 157.31, 155.83, 
152.10, 142.98, 141.94, 132.38, 130.65, 124.57, 120.06, 117.58, 114.56, 104.99, 55.67. ESI-
HRMS:m/z344.06989 [M+H]+ (calc. for C16H13N3O4S: 344.06995[M+H]+). 
4-(3-(6-methoxybenzo[d]thiazol-2-yl)thioureido)benzoic acid (14) 
M.p. 278 °C decomp. Yield 95%. 1H NMR (500 MHz, DMSO-d6): 6 (ppm) 12.67 (br s, 1H), 10.70 (br s, 
1H), 7.91 (m, 4H), 7.49 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.04 (dd, J = 8.8, 2.5 Hz, 1H), 3.80 
(s,3H).13C NMR (126 MHz, DMSO-d6): d (ppm) 182.47, 167.17, 156.08, 143.81, 132.24, 129.89, 
128.53, 
125.15, 120.84, 115.32, 114.89, 106.10, 55.70. ESI-HRMS:m/z360.04681 [M+H]+ (calc. for 
C16H13N3O3S2: 360.04711[M+H]+). 
4-(3-(6-methoxybenzo[d]thiazol-2-yl)guanidino)benzoic acid (15) 
The crude product was purified using column chromatography. 
M.p. 275–277 °C. Yield 17%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.61 (br s, 1H), 9.38 (br s, 1H), 8.12 
(br s, 2H), 7.91 – 7.87 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.6 Hz, 1H), 6.93 
(dd, J = 8.8, 2.6 Hz, 1H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.03, 167.10, 155.47, 
153.07, 145.49, 143.47, 132.04, 130.34, 124.30, 119.86, 118.95, 113.76, 104.94, 55.55. ESI-HRMS: 
m/z343.08539 [M+H]+ (calc. for C16H14N4O3S: 343.08594[M+H]+). 
4. RESULTS AND DISCUSSION 
Design of novel compounds originates from the previously identified ABAD/ 17β-HSD10 
modulator frentizole and its analogues [13–15].Our novel compounds consist of three substructural 
parts i.e. a benzothiazole moiety [38], a linker and a phenyl moiety (Fig. 3). The benzothiazole moiety 
was substituted in position 6 with a methoxy group (the same as is found in the parent compound 
frentizole), fluorine or an ethylcarboxyl group were used at the same position to investigate whether a 
change in spatial size, lipophilicity or amount of hydrogen bond acceptors/donors (HBA/HBD) in this 
part of the molecule would result in a change of inhibitory ability. Three different linkers where used to 
investigate difference(s) between a hydrophilic urea (H-bond acceptor; present in parent compound 
frentizole), guanidine (H-bond donor) linkers and the rather more lipophilic thiourea linker. The phenyl 
moiety was either non-substituted (similar to the parent compound frentizole) or substituted in the 4-
position with either a hydrophilic carboxyl and hydroxyl functional groups (capable of creating hydrogen 
bonds) or a slightly lipophilic methoxy moiety. Frentizole was also synthesized as a reference compound. 
 
Figure 3: Design of novel frentizole analogues. 
Generally, the synthesis started with activation of the corresponding 2-aminobenzo[d]thiazole 
using 1,1’-carbonyldiimidazole resp. 1,1’-thiocarbonyldiimidazole (Scheme 1),only the ethyl 
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2-aminobenzo[d]thiazole-6-carboxylate was prepared in a separate step by treating 4-
aminobenzoatewith potassium thiocyanate and bromine in acetic acid (Scheme 1) [39].In the next 
step, the reactive imidazolyl intermediate was treated with the corresponding aniline to obtain a 
non-symmetrically substituted urea or thiourea product (Scheme 1). 
 
Scheme 1: Synthesis of urea and thiourea derivatives. Reagents and conditions:(a) KSCN, Br2, 
AcOH, rt; (b1) CDI,DCM/DMF, reflux; (b2) SCDI, MeCN, reflux; (c) aromatic amine, DMF, 60°C. 
Guanidine analogues were prepared by treating corresponding thiourea with mercury oxide in 
methanolic ammonia solution (Scheme 2). Guanidine hydrochloride with improved solubility in water 
(suitable for potential in vivo testing) was prepared by stirring guanidine base 12 in mixture of diethyl 
ether and THF saturated by gaseous hydrochloric acid (Scheme 2). 
 
Scheme 2: Synthesis of guanidine analogues. Reagents and conditions: (a) NH3, HgO, MeOH, rt; (b) 
sat. HCl in THF, Et2O, rt. 
The ability of the synthesised compounds to modulate ABAD/17β-HSD10 activity was assessed 
by a spectrophotometric assay that was formerly outlined by Hroch et al. [24]. An initial compound screen 
was performed using each compound at 100 μM concentration. All tested compounds, except of the 
standard frentizole, were found to be capable to markedly decrease the activity of the ABAD enzyme, 
with nine compounds (2, 4, 5, 8, 9, 11–14) decreasing the activity by more than 50%.A subsequent 
compound screen was performed at 25 μM in an attempt to isolate the most potent inhibitors. At this 
lower concentration, compounds 2, 5, 9 and 12 were found to retain a similar level of inhibition as that 
seen at 100 μM, whilst the remaining inhibitors showed less marked inhibition (Table 1). Establishing of 
the SAR for the presented set of compounds was, however, a difficult task, as there were no clear 
correlations between the structure of compounds and their inhibitory activity. 
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There was only one observed trend when the thiourea linked compounds (e.g. 2 and 5) showed mostly 
higher potency compared to the analogous ureas and guanidines. Nevertheless, the best inhibition 
was found for the guanidine 12. Different substitutions of the benzothiazole and/or phenyl moieties 
of the parent frentizole had their effects on the compounds’ activity, but without any obvious logical 
order. 
Table 1: Relative ABAD/17β-HSD10 activity in the presence of each compound at concentrations of 100 
μM and 25 μM (presented as % of control ± SEM). Values shown are an average of two independent 
experiments, each with three technical repeats. 
 
 
Compound R1 R2 R3 
100 µM 25 µM 
(% Activity ± SEM) 
control --- --- --- 100.0 ± 0.11 100.0 ± 0.20 
frentizole (1) OMe O H 102.9 ± 2.98 97.4 ± 0.82 
2 OMe S H 34.8 ± 1.42 39.8 ± 0.44 
3 OMe NH H 61.8 ±5.87 57.9 ±3.91 
4 F O H 41.0 ± 0.61 69.2 ± 0.40 
5 F S H 23.9 ± 0.69 29.0 ± 0.23 
6 F NH H 81.0 ±4.78 86.6±1.43 
7 COOEt O H 64.3 ±1.56 79.2 ±1.60 
8 COOEt S H 36.6 ± 0.33 45.5 ± 0.33 
9 COOEt NH H 35.6 ±2.45 32.0±3.00 
10 OMe O OMe 62.2 ± 0.93 69.7 ± 0.42 
11 OMe S OMe 46.9 ± 1.50 60.9 ± 0.74 
12 OMe NH OMe 17.9 ± 0.71 17.0 ± 0.09 
13 OMe O COOH 41.1 ± 0.47 62.4 ± 0.29 
14 OMe S COOH 29.3 ± 0.76 47.0 ± 0.34 
15 OMe NH COOH 86.0 ±6.23 104.2 ±4.32  
To further assess the potency of the two most active inhibitors, compounds 5 and 12, ABAD/ 
17β-HSD10 activity was measured in the presence of increasing concentrations of the two inhibitors 
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and their IC50 values calculated using GraphPad Prism. Relative IC50 value of 3.06 ± 0.40 μM was 
found for compound 12 (Fig. 4). 
 
Figure 4:  IC50 determination for compound 12. 
Compound 5 produced an inconclusive dose response curve and a relative IC50 value could not 
be determined. Further analysis of this compound revealed that the inhibition was reversed upon the 
addition of dithiothreitol (DTT), indicating the inhibition is likely due to the formation of a disulphide bond 
to an active site cysteine residue (Fig. 5). The DMSO control and 12 showed little change in ABAD/ 17β -
HSD10 activity with inhibition remaining constant under the addition of DTT. However compound 5 
showed a reversal in ABAD/ 17β -HSD10 inhibition upon the addition of DTT with activity values nearly 
returning to the control levels. As many other enzymes exhibit similar properties containing active site 
cysteine residues (e.g. tyrosine phosphatises [40]) this could prove difficult to obtain specificity for 
ABAD/178-HSD10 for such type of thiourea linked compounds. From this point of view, the thiourea 
moiety seems to be unlikely used for further design of ABAD/ 17β -HSD10 inhibitors for the lack of 
specificity. 
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 Figure 5: Relative ABAD/17β-HSD10 activity in the presence of each compound at concentrations of 25 
μM and 100 μM with and without the addition of 5 mM DTT (presented as % of control ± SEM). 
The cytotoxicity of the two most potent inhibitors 5 and 12 was assessed using LDH and MTT 
assay. Cytotoxicity assessment revealed that compound 12 is one order of magnitude less toxic when 
compared to 5 using two different assays and that its toxicity is at similar level and comparable to 
parent frentizole (Table 2). Both IC50 values obtained for 5 were found similar and it plausibly suggests 
that the compound 5does not affect the electron transport chain (ETC) of mitochondria (i.e. compound 
5 does not inhibit enzymes of ETC) [35]. Differently in the case of compound 12, the IC50 value obtained 
via a MTT assay was found lower than the LDH assay result, which could be hypothesized to its influence 
of ETC. However, only small differences between both assays were found that plausibly means only 
minor influence of mitochondrial ETC and should be further explored for this kind of molecules. 
Table 2: Cytotoxicity assessment of frentizole and the most promising inhibitors 5 and 12. 
 
Compound 
IC50 (µM ± SEM) 
LDH MTT  
frentizole 46 ± 6 38 ± 5 
 
5 3.5 ± 0.2 3.1 ± 0.4 
12 51 ± 11 23 ± 6  
The physical-chemical properties were calculated (ACDLabs PhysChem Suite 2014 [20]) and/or 
experimentally measured [41] for the two most potent compounds 5 and 12 and the parent compound 
frentizole (Table 3). The obtained data were compared with optimal properties for CNS targeted drugs 
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[42–44]. All compounds complied with the optimal values for molecular weight, H-bond 
acceptors/donors, number of rotatable bonds and ClogP/ElogP values. CLogD7.4/ELogD7.4 values 
slightly diverged from the optimal range in case of 5 and 12 and all three compounds showed 
higher than optimal values of total polar surface area (tPSA). Regarding solubility, then only 
compound 5 did not fit the optimal range for the calculated logS7.4. Generally, a good correlation 
between the experimental and calculated logP and logD7.4 values was found. Taken together, the 
compounds 5 and 12 were predicted to penetrate the blood-brain barrier and thus might act within 
the CNS. However, for future structural design, it will be advantageous to improve some of the 
physical-chemical properties, especially the tPSA. 
Table 3: Physical-chemical properties of frentizole and the most potent I nhibitors 5 and 12 compared 
to optimal values for CNS targeted drugs [42–44]. 
 
Compound Mw 
H-bond  
acceptor/donor 
Rot. bonds tPSA (Å2) ClogP ELogP±SD ClogD7.4 ELogD7.4 ± SD ClogS7.4 
Optimum ≤450 ≤7/≤3 <8 ≤(60-70) 1-5 1-5 0-3 0-3 >(-4.5) 
frentizole 299.35 5/2 3 91.49 3.2 nd 2.5 nd -3.7 
5 303.38 3/2 4 97.28 3.5 4.1 ± 0.4%o 3.5 4.1 ± 1.2%o -4.6 
12 328.39 6/3 6 107.50 3.3 3.4 ± 0.5%o 3.2 3.4 ± 0.1%o -3.6 
* nd = not determined 
QSAR analyses employing MLR and a systematic variable selection algorithm provided 
statistically significant and robust model for prediction of the ABAD/ 17 β -HSD10 inhibition at the 
inhibitor concentration of 25 mM. In Table 4, the selected molecular descriptors, regression  
coefficients b, standard deviations of regression coefficients (STD(b)), Student’s t’s, and coefficients of 
determination V2 for prediction of the variable by the others variables in the model. According to  
Student’s t’s, all the selected molecular descriptors are statistically significant, although relatively high  
values of V2 reveal considerable inter-correlation between the predictors Mv, JGI6 and Vs.  
Table 4: Description of the best MLR QSAR model for compounds 1-15 and their inhibition activities 
towards ABAD/ 17β-HSD10. 
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Statistical criteria for the best three parametric MLR QSAR model found, such as coefficient  
of determination R2, Fisher-Snedecor F, standard residual deviation s, adjusted coefficient of 
determination R2adj, adjusted Fisher-Snedecor FIT, and cross-validated coefficient of determinations by 
leave-one-out Q2LOO and leave-30%-out Q2LMO-30% techniques, are summarized in Table 5. Q2LMO-30% values 
were determined as a mean value of 1000 repetitions of random selection of 30% compounds from 
the complete set of 1-15. The relationship between the real and predicted inhibition potencies of the 
compounds is outlined in Fig.  6. 
Figure 6: Real and calculated inhibition potencies of compounds 1-15 by the best MLR QSAR model. 
Besides cross-validations of the best QSAR model, we also evaluated the model 
performance after replacement of the y vector of inhibition potencies by random variables with 
normal distribution  (i.e. randomized y) or by its random permutation (i.e. scrambled y). Since 
randomization and scrambling might provide a vector with similar values to the original vector, 
coefficients of determination for the altered and real biological activities are mentioned as R2r/o 
and R2s/o in Table 5.  High values of R2 and F confirm that the QSAR model is internally predictive 
and statistically significant.  Robustness of the model is proved by very high values of cross-
validated coefficients of determination  
Vs 2.537 0.18438 13.759 0.8130 
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Q2LOO and Q2LMO-30%. Drop of all these statistical criteria after randomization and scrambling further 
confirms that the QSAR model is capable to discriminate chance factors in the input. However, the 
QSAR model was built on 15 compound and a pool of several thousand molecular descriptors, and, 
thus, it has to be taken with caution.  
Table 5: Statistical criteria for the best MLR QSAR model representing compounds 1-15 and their 
inhibition activities towards ABAD/ 17β-HSD10. 
The domain of applicability of the best QSAR model was demonstrated by William’s plot, which displays 
possible outliers in a conjugate chemical space of the biological activities and the selected molecular 
descriptors (Fig.  7). Only compound 12, which exhibited the strongest inhibition activity for ABAD/ 
17β-HSD10, is relatively distant from the main cluster of compounds. In general, the QSAR model is 
well representative for the solved problem.  
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 Figure 7: William’s plot representing compounds 1-15 in a projection of the chemical space 
delimited by the MLR QSAR model. No compounds studied exhibit significant outlying, which 
confirms suitability of the model definition.  
The above-mentioned statistical validations clearly showed that the developed MLR QSAR 
model is significant, robust and applicable for ABAD/17β-HSD10 inhibition predictions. The model 
is built only of three variables: Mv - mean atomic van der Waals volume scaled on carbon atom, 
JGI6 - mean topological charge index of order 6, and Vs - V total size index weighted by I-state, 
which enables relatively simple interpretation. If Mv is higher, the observed inhibition potency for 
ABAD/17β-HSD10 is stronger. This feature may be implied if the carbonyl group is replaced by 
thiocarbonyl or imino functions. JGI6 descriptor expresses the total charge transfer between 
atoms at topological distance of 6, and, thus, it is closely related with substitutions at peripheral 
molecular sites and molecular polarity. The higher the charge transfer (i.e. JGI6), the stronger 
inhibition of ABAD/17β-HSD10 is elicited. JGI6 descriptor achieves maximal values for compounds 
7-12, which are substituted with two 4-methoxy or one 4-ethyl carboxylate functions. On the other 
hand, Vs molecular descriptor, which belongs to WHIM group, should be less in order to support 
the inhibition activity. As Vs reflect the spatial molecular extent, a smaller molecules may induce 
a stronger inhibition. Nonetheless, Mv and Vs have opposite meaning which suggests that a certain 
optimum of atomic and total molecular size needs to be found.  
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Pharmacophore analysis of the studied compounds 1-15 in LigandScout 3.1 provided 
another insight into the relationships between the structure and activity of ABAD/17β-HSD10 
inhibitors. By training on the most active substances, a pharmacophore hypothesis was derived 
and all the compounds were scored according to their fit to it. In Fig.  8., an alignment of 
compounds 5 and 12 with the proposed pharmacophore is demonstrated. Since the set of studied 
compounds exhibit a high degree of structural similarity, discrimination of inactive structural cores 
could not fully manifest in the calculations. The present pharmacophore analysis indicated 
practically the whole structure of compounds 5 or 12 as a pharmacophore. Discriminative power 
of the pharmacophore model was achieved mainly due to defining exclusion volumes, which 
enabled differentiation of the most active  compounds (e.g. 5, 12, 9) from the least active ones 
(e.g. 15, 1). Unfortunately, a robust pharmacophore-based QSAR model giving correct 
classification all the tested compounds 1-15 according to their inhibition potency was not achieved 
by this methodology.  
 
Figure  8: A pharmacophore hypothesis derived in LigandScout 3.1 with aligned compounds 5 and 
12.  In the right part of the figure, proposed non-covalent interactions (HBA – hydrogen bond 
acceptor, HBD – hydrogen bond donor, AR – aromatic interaction, H – hydrophobic interactions, 
PI – positively ionisable group) of the ligands with a putative receptor are outlined.  
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CONCLUSION 
In summary, a series of novel ABAD/ 17β-HSD10 inhibitors, analogues of frentizole, have been 
designed, synthesized and evaluated in vitro. Among the 15 prepared compounds, compound 12 was 
found the most promising hit with good inhibitory activity (IC50 = 3.06 ± 0.40 µM) and acceptable 
cytotoxicity profile comparable to the parent frentizole. Together with satisfying physical-chemical 
properties suggesting its capability to permeate through BBB, compound 12 presents a novel lead 
structure for further research and development. On the other hand, compounds encompassing the 
thiourea linker in their structure were found to be improper leads for further development despite their 
good inhibitory activity as they were suggested to act via an unspecific manner and they are possibly 
creating a disulphide bond with the protein’s cysteine residues. 
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